

Therapeutic Class Report Overview - Future Of GPR Agonist

<https://marketpublishers.com/r/T671E52CB0BEN.html>

Date: February 2013

Pages: 20

Price: US\$ 1,000.00 (Single User License)

ID: T671E52CB0BEN

Abstracts

Despite about half a dozen distinct targets having been innovated and introduced in the market for the oral treatment of Type 2 diabetes, ~60% of diabetics still exhibit progressive worsening of glycemic control and ~half of them end up with daily insulin. Increasing epidemiology of Type 2 diabetes due to genetic/lifestyle changes, as well as micro/macrovascular (CV) complication associated with diabetes, demands the researcher to find newer options for treating diabetes which can address other consequences along with HbA1c reduction. Selective PPAR agonists, DGAT1 (diglyceride Acyltransferase 1) inhibitors, GPR (G-protein receptor) agonist, Glucokinase inhibitors are some of the early targets which are in clinical development and have the potential to come into the clinic in the next decade.

Amongst these novel targets, a few candidates from GPR (G-protein couple receptors) agonist are nearing late stage development. Ability to directly modulate insulin and GLP-1 secretion in glucose depended manner is the key trait of this class. Through this, GPR agonist controls hyperglycemia without hypoglycemia, and provides weight loss advantage. Recent publications suggest GPR agonist have complementary action with DPP-IV inhibitors. This report discuss in details about the merits/demerits of developing GPR agonist, pipeline GPR agonist together with sales estimate of key pipeline candidate through 2020 across the world.

Contents

INVESTMENT DRIVERS:

UNMET NEED EXISTS FOR AN ORAL OPTION FOR TREATMENT OF TYPE 2 DIABETES

Massive Epidemiology
Increasing diabetes patient pool
CVD complications associated with diabetes

KEY ATTRIBUTES OF MAJOR ANTI-DIABETIC DRUGS

ORAL ISLETS GPCR AGONIST - DIRECT ACTION ON INSULIN SECRETION AND GLP-1 SECRETION

KEY ADVANTAGE/ RISK OF DEVELOPING GPR AGONIST

DIFFERENCE EXISTS AMONGST GPCR FAMILY

GPR 40 AGONIST VS. GPR 119 AGONIST

PIPELINE GPR AGONIST

TAK-875
ARRY- 981

ANNEXURE- I

TAK-875- SWOT analysis

ANNEXURE- II

TAK-875,- Market Model

I would like to order

Product name: Therapeutic Class Report Overview - Future Of GPR Agonist

Product link: <https://marketpublishers.com/r/T671E52CB0BEN.html>

Price: US\$ 1,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T671E52CB0BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970